Global Typhoid Vaccine Market, By Type (Live Attenuated Vaccine, Monovalent Typhoid Vaccines, Capsular Polysaccharide Vaccines, Conjugate Vaccine, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
According to a study published in Lancet: Infectious Diseases, typhoid infects 21.6 million people worldwide and kills an estimated 200,000 people each year. Furthermore, economic instability in Latin America and other developing economies has resulted in poor sanitation and restricted access to clean water and food, putting people at risk of contracting typhoid. Salmonella typhi produces typhoid fever, which causes symptoms such as a high temperature, headache, loss of appetite, constipation, and nausea. Typhoid fever is primarily spread in areas with poor sanitation and contaminated water. Typhoid fever vaccines are biological formulations that provide immunity and protection against typhoid fever in humans.
Data Bridge Market Research analyses that the typhoid vaccine market was valued at USD 321.48 million in 2021 and is expected to reach USD 719.77 million by 2029, registering a CAGR of 10.6% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Million, Volumes in Units, Pricing in USD
Type (Live Attenuated Vaccine, Monovalent Typhoid Vaccines, Capsular Polysaccharide Vaccines, Conjugate Vaccine, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
EMERGENT (US), Bio Farma (Indonesia), Bharat Biotech (India), BIO-MED (India), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), Lupin (India), Mallinckrodt (US)
Typhoid fever, commonly known as Salmonella typhi or Salmonella enterica serotype Typhi, is a bacterial infection caused by Salmonella typhi. Typhoid fever is most commonly caused by consuming contaminated food or water. Typhoid immunizations help to prevent and protect against typhoid fever. The World Health Organization (WHO) has advised using three types of typhoid vaccines: live attenuated vaccine, capsular polysaccharide vaccines, and conjugate vaccines.
Typhoid Vaccine Market Dynamics
- Rise in the prevalence of typhoid
The surging prevalence of typhoid in various emerging economies is a major factor driving the typhoid vaccine market's growth rate during the forecast period of 2022 to 2029. According to estimates from the International Health Metrics and Evaluation (IHME), over 12 million cases of typhoid fever were reported worldwide in 2016, resulting in around 130,000 deaths. The risk of typhoid is increased among people who do not have access to clean water and sanitation. Poor communities and vulnerable people, such as children, are particularly vulnerable.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of typhoid vaccine market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the typhoid vaccine market. Additionally, the sedentary lifestyle of people and surging geriatric population will result in the expansion of the typhoid vaccine market. Along with this, the presence of immunization campaigns across the globe and favourable reimbursement policies will enhance the market's growth rate.
- Rising number of government initiatives for the development of innovative products
The rising number of government initiatives to develop innovative products is expected to provide beneficial market opportunities. World Health Organization (WHO), Gavi, Bill and Melinda Gates Foundation, and others are all working hard to raise awareness about typhoid and drive immunization efforts against the disease. In December 2017, the World Health Organization (WHO) pre-qualified Typbar TCV, a typhoid conjugate vaccine (TCV) manufactured by Bharat Biotech. The vaccine can now be purchased and delivered to nations funded by UNICEF, the Pan-American Health Organization (PAHO), and the GAVI (Vaccine Alliance). Various companies' regular initiatives are projected to assist market expansion during the forecast period.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the typhoid vaccine market growth during the forecast period.
On the other hand, the high cost associated with vaccine and its development will obstruct the market's growth rate. Developing economies' lack of healthcare infrastructure and the dearth of skilled professionals will challenge the typhoid vaccine market. Additionally, side effects of vaccine such as pain and mild fever will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This typhoid vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the typhoid vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The World Health Organization estimates that 11-20 million cases of typhoid fever occur globally each year, resulting in 128 000–161 000 fatalities.
Typhoid vaccine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Typhoid Vaccine Market
The COVID-19 outbreak has emerged as the world's most serious threat. This problem will be alarming, particularly in developing nations around the world, because it will result in reduced imports owing to global trade disruptions, which will exacerbate shortages of medical supplies and other items, resulting in significant price rises. The World Health Organization and UNICEF have expressed concern over a global fall in youngsters receiving life-saving immunizations. This is due to the COVID-19 pandemic disrupting the delivery and acceptance of vaccine programs. In 2019, UNICEF bought an estimated 2.43 billion vaccination doses for over 100 countries, reaching around 45 percent of the world's children under the age of five. However, companies frequently use product launches and expansion strategies to expand their global footprint and meet rising demand. Market participants frequently use these tactics to enhance their product portfolio.
- In April 2022, The Government of Nepal had announced the launch of a new vaccine campaign called Typhoid Conjugate Vaccine (TCV) into the routine immunization programme across the country. It is in collaboration with Gavi, the Vaccine Alliance, UNICEF, WHO, and other partners. The goal of the program was to obtain 95% coverage of roughly 7.5 million children with the typhoid conjugate vaccine (TCV) while also identifying "zero-dose" children and those who have missed other routine immunizations.
Global Typhoid Vaccine Market Scope
The typhoid vaccine market is segmented on the basis of type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Live Attenuated Vaccine
- Monovalent Typhoid Vaccines
- Capsular Polysaccharide Vaccines
- Conjugate Vaccine
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Typhoid Vaccine Market Regional Analysis/Insights
The typhoid vaccine market is analysed and market size insights and trends are provided by country, type, route of administration, end-users and distribution channel as referenced above.
The countries covered in the typhoid vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the typhoid vaccine market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the 'market's growth rate in this region. Additionally, increasing patient awareness and high demand of vaccine will further propel the 'market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to surging prevalence of typhoid diseases and favourable regulatory guidelines in this region. Also, the development of healthcare infrastructure and rising government initiatives for immunization programs will further propel the market'market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Typhoid Vaccine Market Share Analysis
The typhoid vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to typhoid vaccine market.
Some of the major players operating in the typhoid vaccine market are:
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- bioMérieux SA (France)
- Amgen Inc. (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Sun Pharmaceutical Industries Ltd. (India)
- Lupin (India)
- Mallinckrodt (US)
- EMERGENT (US)
- Bio Farma (Indonesia)
- Bharat Biotech (India)
- BIO-MED (India)